+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P05319(SLC5A8 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P05319(SLC5A8 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The SLC5A8 antibody is a tool used to detect and study the solute carrier family 5 member 8 (SLC5A8), a sodium-coupled transporter protein encoded by the SLC5A8 gene. This transmembrane protein facilitates the absorption of short-chain fatty acids (SCFAs), monocarboxylates (e.g., lactate, pyruvate), and iodide across epithelial cells in tissues such as the intestine, kidney, and thyroid. SLC5A8 is notable for its tumor-suppressive role, as its expression is frequently downregulated in cancers like colorectal, prostate, and breast cancer, often due to promoter hypermethylation. This loss is linked to altered metabolic pathways, such as reduced butyrate uptake (a histone deacetylase inhibitor with anti-cancer effects) and enhanced lactate export in tumor microenvironments.

Antibodies targeting SLC5A8 are critical for investigating its expression patterns, regulatory mechanisms, and functional contributions in both physiological and pathological contexts. They are employed in techniques like immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to assess protein localization and abundance in tissue samples or cell lines. Researchers also use these antibodies to explore SLC5A8's role in gut microbiota interactions, metabolic disorders, and cancer progression. Commercial SLC5A8 antibodies are typically raised against specific epitopes, with validation in knockout models to ensure specificity. Understanding SLC5A8's biology through such antibodies aids in developing therapeutic strategies targeting metabolic reprogramming or epigenetic silencing in diseases.